Novartis sells US rights to Enablex to Warner Chilcott
This article was originally published in Scrip
Executive Summary
Novartis has sold the US rights to the overactive bladder treatment Enablex (darifenacin) for $400 million to Warner Chilcott after a review of its portfolio.